<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">One of the lessons learned from MERS-CoV infections is that host inflammatory responses play a major role in disease progression. This was the base of using interferon-beta in MERS-CoV and COVID-19 infections 
 <xref rid="b0275" ref-type="bibr">[55]</xref>. In the setting of LTX, Interferon-beta had no interactions with immunosuppressive drugs or steroids. Nevertheless, it induces myelosuppression, so it should not be combined with Tocilizumab. Also, potential interaction with chloroquine and hydroxychloroquine may increase its toxicity 
 <xref rid="b0285" ref-type="bibr">[57]</xref>.
</p>
